ABOS (Acumen Pharmaceuticals) Change In Receivables: $0.00 Mil (TTM As of Mar. 2026)

What is Acumen Pharmaceuticals Change In Receivables?

Acumen Pharmaceuticals ABOS -2.59% 34 Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Acumen Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Acumen Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Acumen Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Acumen Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Acumen Pharmaceuticals's liquidation value for the three months ended in Mar. 2026 was $82.25 Mil.

Acumen Pharmaceuticals (NAS:ABOS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Acumen Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Acumen Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Acumen Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	128.398	-	46.153	+	0.75 * 0	+	0.5 * 0
=	82.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Change In Receivables Related Terms

Acumen Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Change In Receivables can be seen below:

Acumen Pharmaceuticals Change In Receivables Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Receivables

Get a 7-Day Free Trial

0.00

Acumen Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Receivables	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

34GF Score

Acumen Pharmaceuticals Inc ABOS

Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Acumen Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Change In Receivables →

What does a Change In Receivables of $0.00 Mil mean?

Acumen Pharmaceuticals (ABOS) has a Change In Receivables of $0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Acumen Pharmaceuticals and its competitors.

Is Acumen Pharmaceuticals' Change In Receivables too high?

Acumen Pharmaceuticals' current Change In Receivables is $0.00 Mil. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does Acumen Pharmaceuticals' Change In Receivables compare to YDES and PYXS?

Acumen Pharmaceuticals' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Receivables for a Biotechnology company?

A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Receivables mean?

A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Acumen Pharmaceuticals stock overvalued right now?

Acumen Pharmaceuticals (ABOS) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Receivables calculated?

Change In Receivables is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Change In Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies YDES PYXS CRBU PRQR CRBP NRXP LENZ KRRO ANTX OKUR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465

Website https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

34GF Score

Get the complete analysis for ABOS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63

Price

View ABOS Analysis

See Change In Receivables data for all stocks →